Skip to main content
Fig. 3 | Microbial Cell Factories

Fig. 3

From: Design and development of a chimeric vaccine candidate against zoonotic hepatitis E and foot-and-mouth disease

Fig. 3

Expression and purification of the HEV-FMDV chimeric proteins. a A 15% SDS-PAGE gel showing the overexpression of Seq 8, Seq 8-P166, Seq 8-P216 and Seq 8-P222 at the expected molecular weights of 9.4, 27.4, 33.4 and 33.9 kDa respectively; and no extra-bands are visible before the IPTG induction (negative control). M: molecular weight marker; C (−): negative control, before IPTG induction; C (+): induction of P222 expression as a positive control. b SDS-PAGE analysis of the solubility of the expressed proteins; P: pellet (insoluble fraction); S: supernatant (soluble fraction). c SDS-PAGE analysis of the purified FMDV antigen and HEV-FMDV chimeric proteins; M: molecular weight marker; CL: cell lysates after passing through the Ni–NTA agarose column; E1 and E2: elution 1 and elution 2 respectively. d Determination of the protein concentrations using the Bradford protein assay: the protein concentration was calculated in the diluted samples then multiplied by 5 (dilution factor) to determine the concentrations in the stock solutions

Back to article page